Abstract: This invention relates to a novel method of decreasing porosity of ceramics produced by sol-gel processing. The process of preparing chemically bonded sol-gel ceramics comprises phosphating a sol-gel derived oxide or hydrated oxide and polymerizing the phosphated product with heat treatment. Such combined sol-gel/chemical bonding process can be used to fabricate dense, thick ceramics or ceramic coatings for a variety of applications, including high temperature corrosion protection, wear resistance, dielectric properties, non-sticky surfaces, bio-active ceramics, thermal barrier ceramics, non-wetted surfaces, and others.

Abstract: Mutant glycosidase enzymes are formed in which the normal nucleophilic amino acid within the active site has been changed to a non-nucleophilic amino acid. These enzymes cannot hydrolyze disaccharide products, but which can still form them. Using this enzyme, oligosaccharides are synthesized by preparing a mixture of an &agr;-glycosyl fluoride and a glycoside acceptor molecule; enzymatically coupling the &agr;-glycosyl fluoride to the glycoside acceptor molecule to form a glycosyl glycoside product using the mutant glycosidase enzyme; and recovering the glycosyl glycoside product. Particular enzymes include a mutant form of Agrobacterium &bgr;-Glucosidase in which the normal glutamic acid residue at position 358 is replaced with an alanine residue.

Abstract: A method for reducing or preventing the effects of inflammation arising from injured tissue, which method comprises the steps of: a. bringing the injured tissue, or pre-injured tissue, into contact with a photosensitizing agent capable of penetrating into the tissue, resulting in the desired degree of biodistribution in less than one hour; and b. exposing the tissue thus contacted to light having a wavelength absorbed by the photosensitizing agent for a time sufficient to reduce or prevent inflammation in the exposed tissue, but not so long as to cause necrosis or erythema of the exposed tissue, or a pharmaceutical composition or an article for reducing or preventing the effects of inflammation arising from injured tissue. The composition comprises: a. from about 1 &mgr;/mL to about 2 mg/mL of a photosensitizing agent capable of penetrating into the injured tissue, or pre-injured tissue, resulting in the desired degree of biodistribution less than one hour; and b. a pharmaceutically acceptable carrier.

Abstract: Nucleic acid molecules encoding an enzyme involved in very long chain fatty acid (VLCFA) elongation in plants are disclosed. The invention includes a cDNA, genomic clone and encoded protein, as well as plants having modified VLCFA composition, such as modified epicuticular waxes, and methods of making such plants.

Abstract: In one aspect, the invention provides a diagnostic method for identifying psoriatic plaques in which Porphyrins, particularly protoporphyrin IX, are elevated as compared to normal skin and skin of patients with other dermatological diseases, including other forms of psoriatic plaque. Psoriatic plaques with elevated porphyrin levels may be detected by fluorescence and spectral analysis. Endogenous porphyrins in psoriatic plaques may be activated with visible light to treat psoriatic plaques having elevated porphyrin concentrations. Skin conditions may be optimized to increase the endogenous concentration of porphyrins in psoriatic plaques. A topical formulation may be applied to psoriatic plaques to optimize skin conditions such as pH, iron concentration, temperature, hydration, calcium concentration, oxygenation, electrical conductivity and estrogen concentration to increase the concentration of endogenous porphyrins.

Abstract: Organic complexes of vanadium are provided, having the general structure VL3, where V is vanadium(III) and L is a monoprotic bidentate ligand that forms a five-membered, unsaturated vanadium containing ring, having vanadium coordinating oxygen or sulfur ring heteroatoms, and where the vanadium containing ring is fused to a six-membered heterocyclic ring. Preferably L is a hydroxypyrone or a hydroxypyridinone. The complexes have a number of uses, including the treatment of elevated blood glucose and related disorders, treatment of proliferative disorders, etc.

Abstract: Photodynamic therapy to prevent secondary cataracts is effected using photosensitizers such as green porphyrins as photoactive agents to destroy remnant lens epithelial cells.

Abstract: A family of proteins, including a specific human protein designated as HIP1, has been identified that interact differently with the gene product of a normal (16 CAG repeat) and an expanded (>44 CAG repeat) HD gene. Expression of the HIP1 protein was found to be enriched in the brain. Analysis of the sequence of the HIP1 protein indicated that it includes a death effector domain (DED), suggesting an apoptotic function. Thus, it appears that a normal function of Huntingtin may be to bind HIP1 and related apoptosis modulators, reducing its effectiveness in stimulating cell death. Since expanded huntingtin performs this function less well, there is an increase in HIP1-modulated cell death in individuals with an expanded repeat in the HD gene. This understanding of the likely role of huntingtin and HIP1 or related proteins (collectively “HIP-apoptosis modulating proteins”) in the pathology of Huntington's Disease offers several possibilities for therapy.

Abstract: Methods and compositions are provided for enhancing feed utilization efficiency in a ruminant animal by adding to the feed a sufficient amount of a nonionic surfactant to enhance the utilization of the feed by the animal. The methods and compositions result in enhanced weight gain and/or milk production by the animal. Preferred nonionic surfactants include polyoxyethylenesorbitan monooleate and polyoxyethylenesorbitan trioleate at a concentration range of from about 0.01 to 1% (w/w) of the dry weight of the feed. A digestion enhancing enzyme and lactic acid bacteria inoculum may also be added to the feed. The surfactant is added to the feed by spraying a dilute solution of the surfactant onto the feed, or by coating the surfactant onto a particulate carrier such as celite, diatomaceous earth or silica and adding the carrier to the feed.

Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone, which does not substantially alter the viability of those cells.

Abstract: Charged particles suspended in a medium such as Fluorinert™ Electronic Liquid are used to electrophoretically control total internal reflection (TIR) at a retro-reflective surface formed on a high refractive index material. Prismatic structures redirect ambient light from an overhead light source toward a display image and then from the image to the region in front of the image, yielding a high contrast reflective display. A transparent planar waveguide front lights the display with sequential flashes of red, blue and green light to generate a full color display. TIR can also be controlled at retro-reflective surfaces by means of a vapor-liquid phase transition, or by changing the absorption coefficient of a material using electrical, chemical and/or electrochemical methods.

Abstract: This invention is related to a novel passive medical device that can be used in surgery to stabilize tissue for anastomosis or other surgical work. More particularly, the tissue stabilization device and surgical arm stabilizes cardiac tissue which enables coronary artery bypass grafting surgeries to proceed while the heart is beating, or during other surgical procedures that require holding or retraction of tissue and arresting blood flow. A surgical arm comprising: (a) a first hollow link; (b) a second hollow link; (c) a hollow universal joint connecting an end of the first link with an end of the second link; (d) a support mount for the first link, the universal joint and the second link; and (e) a hollow tissue stabilizer connected to an end of a hollow link opposite to the hollow link that is proximate the support mount.

Abstract: DNA constructs are provided which code for a chimeric protein in which the C-terminal region corresponds to the extreme C-terminal amino acids of a Caulobacter S-layer protein, fused with a heterologous polypeptide. Bacterial cells containing the DNA constructs, or which express the DNA constructs and secrete the resulting protein, are provided. Chimeric proteins including the C-terminal amino acids of a Caulobacter S-layer protein are provided, including proteins which include antigenic epitopes of the Infectious Hematopoietic Necrosis Virus.

Abstract: Glycosylated acceptors are prepared using glycosyl transferase and activated glycosyl derivatives as donor sugars without the use of sugar nucleotides as donor sugars. A reaction mixture composition containing an activated glycoside derivative such as glycosyl fluoride or glycosyl mesylate, an acceptor substrate such as lactose or other oligosaccharide, a glycosyl transferase and a catalytic amount of a nucleotide phosphate or nucleotide phosphate analog is reacted to produce the glycosylated acceptor. The acceptor substrate may also be a monosaccharide, a fluorescent-labeled saccharide or a saccharide derivative such as an aminoglycoside antibiotic. The glycosyl transferase may be immobilized by removing its membrane-binding domain and attaching in its place a cellulose-binding domain. In another embodiment, a glycosylated acceptor is formed by making a nucleotide phosphate glycoside in situ in a steady state concentration.

Abstract: A novel class of cationic peptides having antimicrobial activity is disclosed. These peptides can be encompassed by the formulas: X1X1PX2X3X2P(X2X2P)nX2X3(X5)o; (SEQ ID NO: 23) X1X1PX2X3X4(X5)rPX2X3X3; (SEQ ID NO: 24) X1X1X3(PW)uX3X2X5X2X2X5X2(X5)o; and (SEQ ID NO: 25) X1X1X3X3X2P(X2X2P)nX2(X5)m; (SEQ ID NO: 26) wherein: m is 1 to 5; n is 1 or 2; o is 2 to 5; r is 0 to 8; u is 0 or 1; X1 is Isoleucine, Leucine, Valine, Phenylalanine, Tyrosine, Tryptophan or Methionine; X2 represents Tryptophan or Phenylalanine X3 represents Arginine or Lysine; X4 represents Tryptophan or Lysine; and X5 represents Phenylalanine, Tryptophan, Arginine, Lysine, or Proline. The invention also provides a method of producing a cationic peptide variant having antimicrobial activity.

Abstract: A method is provided of operating a mass spectrometer apparatus comprising a pair of quadrupole rod sets. Each quadrupole rod set is operated in a mass resolving mode. They may be operated in the same or different stability regions. The rod sets are operated to select essentially ions of the same mass to charge ratio, and are operated such that the combined resolution of the two rod sets is greater than the resolution of either rod set. The rod sets can be operated at relatively low resolution, with the combined peak shape from the two rod sets showing high resolution. This can make up for mechanical imperfections in the rod sets, losses due to high gas pressures, etc. A mass shift can be provided to give the desired resolution. The rod sets can be close coupled, and for this purpose neutralizing capacitors can be provided to prevent electrical interference between adjacent rod sets.

Abstract: A composition and method for inhibiting apoptosis, or decreasing the rate or extent of apoptosis, in target cells. The method comprises the step of the step of contacting the target cells with an apoptosis-regulating amount of at least one cysteine or serine protease inhibitor that: a. inhibits the conversion of the pro-enzyme form of CPP32 to its enzymatically-active form; b. blocks the proteolytic action of activated CPP32 against its cellular substrates; or c. both. The method is particularly applicable to ameliorating the side effects of, or enhancing the selectivity, of photodynamic therapy.

Abstract: A computer-implementable method for estimating the surface area to volume ratio and the surface area of a lung based on x-ray attenuation data obtained from a computed tomography (CT) scan of the lung is disclosed. The method includes obtaining a plurality of CT images that include a lung image from a plurality of subjects. Each of the resulting CT images is displayed such that an x-ray attenuation value is associated with each pixel. Thereafter the lung image is extracted from the CT image. Then, the volume of each lung is calculated based on the plurality of lung images extracted from the plurality of CT images. Also, the volume-of-gas to weight-of-tissue ratio for all of the pixels included in each of the lung images is calculated using the x-ray attenuation value associated with the pixel. The pixel ratio values are used to determine the median volume-of-gas to weight-of tissue ratio for all the pixels included in all the lung images for each lung.

Abstract: A compound having a polysaccharide binding domain such as contained by a cellulose and essentially lacking in polysaccharidase activity is purified from other ingredients in a mixture using an affinity partition system. A mixture containing the compound is contacted with a system containing as a first phase an aqueous solution of oligosaccharide polymer such as cellulose and as a second phase a solution of a polymer such as a poly(ethylene glycol)-poly(propylene glycol) copolymer. The compound petitions into the first phase and binds to the oligosaccharide polymer, preferably with a Ka of 103 to 107, to form a complex. The complex is collected, and the compound is dissociated from the oligosaccharide polymer. The compound may be formed of a non-peptide chemical moiety or a peptide moiety linked to a polypeptide having the polysaccharide binding domain.

Abstract: Aminocyclohexylester compounds, including thioesters, are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the blockade of ion channels and the treatment of arrhythmias.